Вклад участника
Материал из Wiki
- 16:49, 15 марта 2017 (разн. | история) . . (+3453) . . Н The complete quantities of ATP and phosphate in the identical samples for just about every pH had been also identified utilizing luciferase assay and malachite inexperienced assay respectively (Новая страница: «We for that reason utilized radioactive phosphate to watch phosphate bond development in reaction to acid gradient. In get to assess this, [http://www.medchemexpr…») (текущая)
- 16:01, 6 марта 2017 (разн. | история) . . (+3379) . . Н The b-actin expression was assessed as a loading control and used for normalization and quantification (Новая страница: «Alterations in the amounts of overall [http://www.medchemexpress.com/alpha-Amanitin.html 23109-05-9 biological activity] O-GlcNAc modified proteins and p53. Prote…») (текущая)
- 01:37, 4 марта 2017 (разн. | история) . . (+3660) . . Н The energy of this initial structure was minimized with 3,000 steps of conjugated gradient minimization using the CHARMM27 force field (Новая страница: «The uneven device consists of two monomeric molecules of the HiDapET. For cryo-defense, all crystals have been transferred to the mom liquid made up of a 25% comb…»)
- 22:29, 2 марта 2017 (разн. | история) . . (+21) . . м It was reported that Cdk5/p35 complex have been associated with motility and stabilization of growth cone during the axon elongation (текущая)
- 19:52, 28 февраля 2017 (разн. | история) . . (+3547) . . Н Conversely, co-treatment with aucubin or geniposide inhibited phosphorylation and downstream signaling of PERK, eIF2a, and CHOP (Новая страница: «Immunoblotting was done with antibodies in opposition to GRP78, PERK, p-PERK, CHOP, IRE1-a, p-eIF2a, eIF2a, or b-actin. (B) Lysosome fractionation was carried out…») (текущая)
- 16:13, 22 февраля 2017 (разн. | история) . . (+3049) . . Н The experiments shown are representative of at least three others, which gave similar results (Новая страница: «Cell particles ended up removed by centrifugation at 14,000xg for fifteen min at 4 uC, and then a hundred and fifty ml of fifty% [http://www.medchemexpress.com/Ca…») (текущая)
- 08:45, 22 февраля 2017 (разн. | история) . . (+2905) . . Н The mRS at three months is the most prevalent outcome assessment and the preferred outcome measure for treatment trials in acute stroke (The mRS at three months is the most prevalent outcome assessment and the preferred outcome measure for treatment trials in acute stroke) (текущая)